PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 17058803

Pyothorax-associated lymphoma.

Katsuyuki Aozasa
View original source ↗Export metadata ↓

Abstract

In Japan, EBV positive rate in immunocompetent patients with nodal lymphomas is less than 10% in B-cell and 20-50% in T cell lymphoma. Among extranodal lymphomas, EBV positive rate is higher in pyothorax-associated lymphoma (PAL), nasal NK/T-cell lymphoma, and adrenal lymphoma. PAL is non-Hodgkin's lymphoma that develops from chronic pyothorax resulted from artificial pneumothorax for the treatment of lung tuberculosis or tuberculous pleuritis. This disease was originally described by Dr. Aozasa as a distinctive clinicopathologic entity in 1987, and now listed as the disease entity in the WHO classification of Tumours, Pathology & Genetics, Tumours of the Lung, Pleura, Thymus and Heart (2004).

Explore related subjects

Empyema, PleuralHistory, 20th CenturyHistory, 21st CenturyHumansJapanLymphoma, B-CellLymphoma, T-CellNose NeoplasmsPleural NeoplasmsPneumothoraxTuberculosis, PleuralHistorical ArticleJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Katsuyuki Aozasa. 2006. Pyothorax-associated lymphoma.. https://doi.org/10.3960/jslrt.46.5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Intrapleural fibrinolytic therapy for pleural infection.

Pneumonia with secondary pleural infection causes considerable morbidity and mortality. Intrapleural instillation of fibrinolytic agents to dissolve fibrinous adhesions is intended to improve pleural fluid drainage and prevent pleural loculations. In the last 20 years their application in the every day clinical practice has dragged much of attention and several studies have supported their use in the management of parapneumonic pleural effusions (PPE) and pleural empyema (PE). However, recent published data cast doubt on the effectiveness of intrapleural fibrinolytic agents in promoting drainage of infected pleural effusions. Pending future clinical trials, fibrinolytic therapy may be used selectively in patients who fail drainage with appropriately sized, image-guided chest tubes if reasons exist to delay or avoid definitive surgical drainage. The scope of this article is to systematically review evidence for the efficacy of intrapleural fibrinolytic therapy in the treatment of PPE and PE with emphasis on controlled trials and present some of the future perspectives.

Empyema, Pleural↗